Plus Therapeutics (PSTV) Gains from Investment Securities (2010 - 2026)
Plus Therapeutics (PSTV) reported Gains from Investment Securities of $159480.0 for Q1 2026, down 87.43% year-over-year from $1.3 million in Q1 2025, and down 65.77% quarter-over-quarter from $465877.0 in Q4 2025.
Plus Therapeutics (PSTV) Gains from Investment Securities (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has 17 years of Gains from Investment Securities data on file, last reported at $159480.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $159480.0, down 87.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $159480.0 (down 87.43% YoY), and the FY2025 annual result was $465877.0, down 22.16% from the prior year.
- Gains from Investment Securities fell to $159480.0 in Q1 2026 per PSTV's latest filing, from $465877.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $11.3 million in Q3 2025 and troughed at -$4.7 million in Q2 2024.
- A 5-year average of $799412.6 and a median of $159480.0 in 2026 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2023 and 2024: Gains from Investment Securities jumped 299900.0% in 2023, then sank 3750.59% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $641000.0 in 2022, then sank by 89.33% to $68422.0 in 2023, then sank by 30.29% to $47696.0 in 2024, then surged by 876.76% to $465877.0 in 2025, then plunged by 65.77% to $159480.0 in 2026.
- Business Quant data shows PSTV's Gains from Investment Securities at $159480.0 in Q1 2026, $465877.0 in Q4 2025, and $11.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Plus Therapeutics | 35.99 Mn | 20.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 159,480.00 |
| Mar 31, 2026 | 159,480.00 |
| Dec 31, 2025 | 465,877.00 |
| Dec 31, 2025 | 465,877.00 |
| Sep 30, 2025 | 11.27 Mn |
| Sep 30, 2025 | 11.27 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Sep 30, 2024 | 47,696.00 |
| Sep 30, 2024 | 47,696.00 |
| Jun 30, 2024 | -4.69 Mn |
| Jun 30, 2024 | -4.69 Mn |
| Mar 31, 2024 | 163,025.00 |
| Mar 31, 2024 | 163,025.00 |
| Sep 30, 2023 | 68,422.00 |
| Sep 30, 2023 | 68,422.00 |
| Jun 30, 2023 | 128,582.00 |
| Jun 30, 2023 | 128,582.00 |